Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|February 1, 2021
- Pharmaceutical Technology's In the Lab eNewsletter 02-03-2021
- Volume 16
- Issue 2
Contec Launches Sustainable Cleanroom Wipes
Author(s)Pharmaceutical Technology Editors
ReFIBE sterile cleanroom wipes are sustainable polyester wipes made from recycled post-consumer plastic bottles.
Advertisement
Contec announced on Jan. 19, 2020 that it has introduced ReFIBE sterile cleanroom wipes, sustainable polyester wipes made from recycled post-consumer plastic bottles.
According to a company press release, the plastic bottles are first chopped into flakes and cleaned, then the flakes are melted, filtered, and formed into chips, which are melted and made into yarn. Finally, the yarn is knitted into sterile and non-sterile 9” x 9” and 12” x 12” ReFIBE wipes.
Laser-cut with heat-sealed edges, ReFIBE are cleanroom laundered and made with 100% polyester, Contec said in the press release.
“ReFIBE has been such a fulfilling project to work on,” said Amy Russ, global project manager for the Cleanroom Division at Contec, in the press release. “We consider it our responsibility to offer clean, sustainable alternatives to our customers, and ReFIBE wipes are just the beginning. We are excited to develop more sustainable options for both existing Contec products and new innovations in the months and years to come.”
Source:
Articles in this issue
over 5 years ago
Protein Characterization Can Support Regulatory Submissionover 5 years ago
Almac Invests in Expanding Global Biologics Testing SolutionsAdvertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement